Retatrutide

What it is

Retatrutide is an investigational triple hormone receptor agonist being studied for obesity and other metabolic or weight-related conditions. It has a real clinical-development program. That makes the evidence stronger than for many gray-market peptides, but it does not make the drug FDA-approved or validate products sold outside the trials.

What humans actually show

• Published phase 2 obesity trial: A randomized, double-blind, placebo-controlled trial enrolled 338 adults. At 48 weeks, the estimated mean weight change in the highest studied group was −24.2%, compared with −2.1% with placebo. Gastrointestinal adverse events were most common during dose escalation and were more frequent in higher-dose groups.
• TRIUMPH-1 is completed; registry results are not posted: ClinicalTrials.gov records the phase 3 obesity trial as completed with 2,335 participants and explicitly reports “No Results Posted.” Completion is a study milestone. Without posted or peer-reviewed results, PepCurrent does not make an efficacy claim from TRIUMPH-1. (ClinicalTrials.gov — NCT05929066)
• Published phase 3 diabetes trial: TRANSCEND-T2D-1 randomized 537 adults whose type 2 diabetes was inadequately controlled with diet and exercise alone. Over 40 weeks, retatrutide monotherapy improved HbA1c and body weight more than placebo. This was a diabetes trial with no semaglutide or tirzepatide arm. It does not turn the separate TRIUMPH-1 obesity registry record into published results.
• Direct comparisons are still unanswered: TRIUMPH-5, comparing retatrutide with tirzepatide in obesity, was active but no longer recruiting and had no results posted in the July 26 registry check; estimated primary completion was November 2026 and study completion December 2026. TRANSCEND-T2D-2, comparing retatrutide with semaglutide in type 2 diabetes, also had no results posted; estimated primary completion was August 2026 and study completion January 2027. Until results are available, percentages from separate trials cannot answer which drug performs better in a defined population.

FDA and U.S. status

Retatrutide remains investigational as of August 2, 2026. FDA states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.

An investigational drug with successful trials can still have unresolved labeling, manufacturing, surveillance, and benefit-risk questions before approval.

Risks and warning limits

The published phase 2 obesity trial reported gastrointestinal adverse events, with frequency related to dose and escalation, and dose-dependent increases in heart rate that peaked during follow-up and then declined. In TRANSCEND-T2D-1, gastrointestinal events were again the most frequent and were generally described as mild to moderate. Two deaths occurred in one retatrutide group and were reported by the investigators as unrelated to the study drug.

Retatrutide has no FDA-approved prescribing information. Its complete safety profile, contraindications, warnings, and approved-use boundaries cannot be assumed before FDA review and final labeling.

PepCurrent does not provide dosing, sourcing, trial-enrollment, or personalized weight-loss advice.

What would change this answer

• Peer-reviewed publication of the TRIUMPH-1 phase 3 obesity results
• Results from the direct retatrutide-versus-semaglutide and retatrutide-versus-tirzepatide trials
• FDA submission, review, and any future approved labeling
• Additional cardiovascular and long-term safety outcomes
• Enforcement involving products sold as retatrutide before approval

Sources and records

• Jastreboff et al., 2023 — Phase 2 obesity trial
• Bajaj et al., 2026 — TRANSCEND-T2D-1 phase 3 diabetes trial
• ClinicalTrials.gov — TRIUMPH-1, NCT05929066
• ClinicalTrials.gov — TRIUMPH-5, NCT06662383
• ClinicalTrials.gov — TRANSCEND-T2D-2, NCT06260722
• FDA concerns with unapproved GLP-1 drugs

Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.